Unknown

Dataset Information

0

Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives.


ABSTRACT: Glioblastomas are aggressive, fast-growing primary brain tumors. After standard-of-care treatment with radiation in combination with temozolomide, the overall prognosis of newly diagnosed patients remains poor, with a 2-year survival rate of less than 20%. The remarkable survival benefit gained with immunotherapy in several extracranial tumor types spurred a variety of experimental intervention studies in glioblastoma patients. These ranged from immune checkpoint inhibition to vaccinations and adoptive T cell therapies. Unfortunately, almost all clinical outcomes were universally disappointing. In this perspective, we provide an overview of immune interventions performed to date in glioblastoma patients and re-evaluate their performance. We argue that shortcomings of current immune therapies in glioblastoma are related to three major determinants of resistance, namely: low immunogenicity; immune privilege of the central nervous system; and immunosuppressive micro-environment. In this perspective, we propose strategies that are guided by exact shortcomings to sensitize glioblastoma prior to treatment with therapies that enhance numbers and/or activation state of CD8 T cells.

SUBMITTER: Weenink B 

PROVIDER: S-EPMC7140029 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives.

Weenink Bas B   French Pim J PJ   Sillevis Smitt Peter A E PAE   Debets Reno R   Geurts Marjolein M  

Cancers 20200322 3


Glioblastomas are aggressive, fast-growing primary brain tumors. After standard-of-care treatment with radiation in combination with temozolomide, the overall prognosis of newly diagnosed patients remains poor, with a 2-year survival rate of less than 20%. The remarkable survival benefit gained with immunotherapy in several extracranial tumor types spurred a variety of experimental intervention studies in glioblastoma patients. These ranged from immune checkpoint inhibition to vaccinations and a  ...[more]

Similar Datasets

| S-EPMC9266573 | biostudies-literature
| S-EPMC7565291 | biostudies-literature
| S-EPMC6099643 | biostudies-literature
2019-08-10 | GSE135618 | GEO
| S-EPMC4793725 | biostudies-literature
| S-EPMC6307608 | biostudies-literature
| S-EPMC4867303 | biostudies-literature
| S-EPMC7281703 | biostudies-literature
| S-EPMC7476347 | biostudies-literature
| S-EPMC9950866 | biostudies-literature